What the peptide policy record says

What does a withdrawn nomination mean?

BPC-157 has a withdrawn nomination entry on FDA’s bulk-substance page. The page’s own currency stamp is April 22, 2026, and other peptide entries share that table. The same table keeps FDA’s safety concerns next to each entry.

The page does not supply a withdrawal date for each substance. Its April 22, 2026 currency date is not a date on which all those individual entries moved.

Taking back a nomination does not by itself give permission to compound BPC-157. Separately, an October 30, 2026 HHS draft describes when it plans to hold back enforcement over BPC-157 prescriptions prepared for individual patients. That draft requires a single active ingredient and sets limits on ingredient forms and how the drug is given. Blends and section 503B facilities are excluded. It gives no FDA approval or right to compound. These distinctions were checked November 3, 2026.

Ask a service what it thinks the withdrawal proves about the exact preparation proposed to you. Taking back a nomination is not the same act as a regulator approving a drug.

What is known about the committee?

FDA’s compounding advisory committee met July 23–24, 2026 to consider peptide ingredients for the 503A bulks list. That list governs raw ingredients for patient-specific compounding. The meeting materials covered seven peptides and their forms.

HHS, the federal health department, reported in its October 30, 2026 policy that six of the seven peptides won favorable votes from the committee. The FDA meeting page checked November 3, 2026 had neither a transcript nor minutes. It also had no record of individual votes.

HHS’s report supplies an official account of the outcome, though it is not FDA meeting minutes. It gives no totals for the votes. Leaving emideltide out of the policy does not tell how the committee voted on that peptide.

A committee vote gives advice. The framework checked November 3, 2026 requires notice-and-comment rulemaking, a public process for changing the codified ingredient list, before advice changes the list.

What does the October draft cover?

In its October 30, 2026 draft, HHS said it planned to hold back enforcement over certain prescriptions for semax, KPV, MOTS-c, TB-500, epitalon, and BPC-157. This applies to individual patients’ prescriptions prepared by doctors or state-licensed pharmacies that meet the policy’s conditions.

Each medicine must have only one active ingredient, in a form and given in a way the draft covers. Blends do not qualify, and neither do section 503B outsourcing facilities. As of November 3, 2026, none of these six ingredients is on the official 503A bulks list for patient-specific compounding.

This is not FDA approval, a change in the law, or a promise of a right to compound. The draft is nonbinding, and HHS can revisit the approach for safety or quality concerns.

Ask which conditions the proposed preparation is said to meet. The answer needs to concern the ingredient, the route, and the order for that person rather than the existence of the draft alone.

What remains a separate care question?

FDA’s published concerns checked November 3, 2026 include immune reactions, impurities, difficulty establishing ingredient identity, and limited human safety information for certain peptide preparations. The policy debate does not fill that gap in evidence about people.

Ask the clinician what evidence supports the use proposed to you and what uncertainty remains. Also ask what would be monitored and who answers if a problem occurs. Those are care questions even when a policy headline sounds encouraging.

Keep a copy of the precise claim and the document used to support it. Then ask whether the claim concerns approval, compounding conditions, or enforcement plans. Clear wording helps prevent a real policy event from being stretched into a broader promise.